Abstract:Antitumor activity using 59 cancer cell lines and enzyme inhibitory activity of a newly synthesized pyrazoline-linked 4-methylsulfonylphenyl scaffold (compounds 18a–q ) were measured and compared with those of standard drugs. Pyrazolines 18b , 18c , 18f , 18g , 18h , and 18n possessed significant antitumor activity, with a positive cytotoxic effect (PCE) of 22/59, 21/59, 21/59, 48/59, 51/59, and 20/59, respectively. The cancer cell lines HL60, MCF-7, and MDA-MB-231 were used to measure the IC 50 values of derivatives 18c , 18g , and 18h via the MTT assay method, and the results were compared with those of reference drugs. Derivatives 18g and 18h showed potent and broad-spectrum antitumor activities against HL60 (IC 50 of 10.43, 8.99 μM, respectively), MCF-7 (IC 50 of 11.7 and 12.4 μM, respectively), and MDA-MB-231 (IC 50 of 4.07 and 7.18 μM, respectively). Compound 18c exhibited strong antitumor activity against HL60 and MDA-MB-231 cell lines with IC 50 values of 8.43 and 12.54 μM, respectively, and moderate antitumor activity against MCF-7 cell lines with an IC 50 value of 16.20 μM. Compounds 18c , 18g , and 18h remarkably inhibited VEGFR2 kinase (IC 50 = 0.218, 0.168, and 0.135 μM, respectively) compared with the reference drug sorafenib (IC 50 = 0.041 μM). Compounds 18g and 18h effectively inhibited HER2 kinase (IC 50 = 0.496 and 0.253 μM, respectively) compared with erlotinib (IC 50 = 0.085 μM). Compound 18h inhibited EGFR kinase (IC 50 = 0.574 μM) with a potency comparable with that of the reference drug erlotinib (IC 50 = 0.105 μM). Pyrazolines 18c , 18f , and 18h arrested the S/G2 phase of the cell cycle in HL-60 cells. In addition, derivatives 18c , 18f , and 18h revealed lower Bcl-2 protein expression anti-apoptotic levels and higher Bax, caspase-3, and caspase-9 expression levels. Molecular docking studies of derivative 18h into the binding sites of EGFR, HER2, and VEGFR2 kinases explored the interaction mode of these pyrazoline derivatives and their structural requirements for antitumor activity.

Pyrazolo[1,5-a]pyrimidin-7-yl Phenyl Amides As Novel Antiproliferative Agents: Exploration of Core and Headpiece Structure-Activity Relationships.

Design, Synthesis, and Anticancer Activity Evaluation of Hybrids of Azoles and Barbituric Acids.

Synthesis, SAR Study and Biological Evaluation of Novel Pyrazolo[1,5-A]pyrimidin-7-yl Phenyl Amides As Anti-Proliferative Agents

Novel secondary pyridinyl amides: Synthesis, in vitro antiproliferative screenings, and molecular docking studies

Synthesis and Biological Evaluation of Compounds Which Contain Pyrazole, Thiazole and Naphthalene Ring As Antitumor Agents.

(6,7-Dimethoxy-2,4-dihydroindeno[1,2-c]pyrazol-3-yl)phenylamines: Platelet-Derived Growth Factor Receptor Tyrosine Kinase Inhibitors with Broad Antiproliferative Activity Against Tumor Cells

Synthesis, Docking, and Dynamic Studies of New Pyrano‐[3,2‐e]‐Pyrazole Fused 1,2,4‐Triazolo‐[4,3‐c]‐pyrimidine Analogues as Anticancer Agents

Design, Synthesis and Biological Activity of Pyrazolo[3,4-d]pyrimidine Derivatives Containing Indole Moiety

Synthesis, enzyme inhibition assay, and molecular modeling study of novel pyrazolines linked to 4-methylsulfonylphenyl scaffold: antitumor activity and cell cycle analysis

Synthesis of New Pyrazolo[3,4-d]pyrimidine Derivatives: NMR Spectroscopic Characterization, X-Ray, Hirshfeld Surface Analysis, DFT, Molecular Docking, and Antiproliferative Activity Investigations

Nature-Inspired 1-Phenylpyrrolo[2,1-a]isoquinoline Scaffold for Novel Antiproliferative Agents Circumventing P-Glycoprotein-Dependent Multidrug Resistance

Identification of Thiazolo[5,4-D]pyrimidine Derivatives As Potent Antiproliferative Agents Through the Drug Repurposing Strategy

Design, Synthesis and Antiproliferative Activity of Novel 5-Nitropyrimidine-2,4-diamine Derivatives Bearing Alkyl Acetate Moiety

Novel 4-phenoxypyridine derivatives bearing imidazole-4-carboxamide and 1,2,4-triazole-3-carboxamide moieties: Design, synthesis and biological evaluation as potent antitumor agents

Design, Combinatorial Synthesis and Biological Evaluations of Novel 3-Amino-1'-((1-aryl-1h-1,2,3-triazol-5-yl)methyl)-2'-oxospiro[benzo[a] Pyrano[2,3-C]phenazine-1,3'-indoline]-2-carbonitrile Antitumor Hybrid Molecules.

Synthesis, anticancer evaluation, CDK2 inhibition, and apoptotic activity assessment with molecular docking modeling of new class of pyrazolo[1,5-a]pyrimidines

Design and Synthesis of Carbothioamide/Carboxamide-Based Pyrazoline Analogs as Potential Anticancer Agents: Apoptosis, Molecular Docking, ADME Assay, and DNA Binding Studies.

Structure–Activity Relationship Studies on Highly Functionalized Pyrazole Hydrazones and Amides as Antiproliferative and Antioxidant Agents

Design, modification and 3D QSAR studies of novel naphthalin-containing pyrazoline derivatives with/without thiourea skeleton as anticancer agents.

Novel pyrano[2,3-c]pyrazolopyrimidines as promising anticancer agents: Design, synthesis, and cell cycle arrest of HepG2 cells at S phase

Synthesis and Biological Evaluation of Novel Pyrazoline Derivatives Containing Indole Skeleton As Anti-Cancer Agents Targeting Topoisomerase II.